ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of “Moderate Buy” by Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $173.00.

A number of equities research analysts recently weighed in on ICUI shares. KeyCorp upped their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Jefferies Financial Group assumed coverage on shares of ICU Medical in a research report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective on the stock. Raymond James increased their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Finally, StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI opened at $168.46 on Monday. The firm has a 50 day moving average of $176.22 and a 200 day moving average of $145.72. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $4.12 billion, a price-to-earnings ratio of -36.86 and a beta of 0.66. ICU Medical has a 52 week low of $83.26 and a 52 week high of $196.26.

Insider Buying and Selling

In related news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $171.84, for a total value of $2,062,080.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,973,261.12. This represents a 10.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. The trade was a 16.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,502 shares of company stock worth $6,573,496 in the last 90 days. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Allworth Financial LP boosted its holdings in ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares during the last quarter. Xponance Inc. boosted its stake in shares of ICU Medical by 6.0% in the second quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock worth $235,000 after buying an additional 112 shares during the last quarter. Equitable Trust Co. raised its position in ICU Medical by 2.2% during the third quarter. Equitable Trust Co. now owns 5,213 shares of the medical instruments supplier’s stock valued at $950,000 after acquiring an additional 112 shares in the last quarter. CWM LLC lifted its holdings in ICU Medical by 18.5% in the second quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock valued at $91,000 after acquiring an additional 120 shares during the period. Finally, Hexagon Capital Partners LLC boosted its position in ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.